RT Journal Article
SR Electronic
T1 Sphincterotomy for Biliary Sphincter of Oddi Disorder and idiopathic Acute Recurrent Pancreatitis: THE RESPOND LONGITUDINAL COHORT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.18.24305985
DO 10.1101/2024.04.18.24305985
A1 Coté, Gregory A.
A1 Elmunzer, B. Joseph
A1 Nitchie, Haley
A1 Kwon, Richard S.
A1 Willingham, Field F.
A1 Wani, Sachin
A1 Kushnir, Vladimir
A1 Chak, Amitabh
A1 Singh, Vikesh
A1 Papachristou, Georgios
A1 Slivka, Adam
A1 Freeman, Martin
A1 Gaddam, Srinivas
A1 Jamidar, Priya
A1 Tarnasky, Paul
A1 Varadarajulu, Shyam
A1 Foster, Lydia D.
A1 Cotton, Peter B.
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.18.24305985.abstract
AB Objective Sphincter of Oddi Disorders (SOD) are contentious conditions in patients whose abdominal pain, idiopathic acute pancreatitis (iAP) might arise from pressurization at the sphincter of Oddi. The present study aimed to measure the benefit of sphincterotomy for suspected SOD.Design Prospective cohort conducted at 14 U.S. centers with 12 months follow-up. Patients undergoing first-time ERCP with sphincterotomy for suspected SOD were eligible: pancreatobiliary-type pain with or without iAP. The primary outcome was defined as the composite of improvement by Patient Global Impression of Change (PGIC), no new or increased opioids, and no repeat intervention. Missing data were addressed by hierarchal, multiple imputation scheme.Results Of 316 screened, 213 were enrolled with 190 (89.2%) of these having a dilated bile duct, abnormal labs, iAP, or some combination. By imputation, an average of 122/213 (57.4% [95%CI 50.4-64.4]) improved; response rate was similar for those with complete follow-up (99/161, 61.5%, [54.0-69.0]); of these, 118 (73.3%) improved by PGIC alone. Duct size, elevated labs, and patient characteristics were not associated with response. AP occurred in 37/213 (17.4%) at a median of 6 months post-ERCP and was more likely in those with a history of AP (30.9 vs. 2.9%, p<0.0001).Conclusion Nearly 60% of patients undergoing ERCP for suspected SOD improve, although the contribution of a placebo response is unknown. Contrary to prevailing belief, duct size and labs are poor response predictors. AP recurrence was common and like observations from prior non-intervention cohorts, suggesting no benefit of sphincterotomy in mitigating future AP episodes.Key MessagesWHAT IS ALREADY KNOWN ON THIS TOPICWHAT IS ALREADY KNOWN ON THIS TOPICIt is not clear if the sphincter of Oddi can cause abdominal pain (Functional Biliary Sphincter of Oddi Disorder) and idiopathic acute pancreatitis (Functional Pancreatic Sphincter of Oddi Disorder), and whether ERCP with sphincterotomy can ameliorate abdominal pain or pancreatitis.WHAT THIS STUDY ADDSWHAT THIS STUDY ADDSUsing multiple patient-reported outcome measures, most patients with suspected sphincter of Oddi disorder improve after ERCP with sphincterotomy.Duct size, elevated pancreatobiliary labs, and baseline patient characteristics are not independently associated with response.There is a high rate of recurrent acute pancreatitis within 12 months of sphincterotomy in those with a history of idiopathic acute pancreatitis.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICYHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICYSince a discrete population with a high (> 80-90%) response rate to sphincterotomy for suspected pancreatobiliary pain could not be identified, there is a need for additional observational and interventional studies that include phenotyping of patients using novel imaging or biochemical biomarkers.There remains a pressing need for quantitative nociceptive biomarkers to distinguish pancreatobiliary pain from other causes of abdominal pain or central sensitization.Discovery of blood-, bile-, or imaging-based biomarkers for occult microlithiasis and pancreatitis may be helpful in predicting who is likely to benefit from sphincterotomy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health under award number R01DK115495 (Cote, Foster, Cotton). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As the lead centers for this study, the Institutional Review Board for Human Research at the Medical University of South Carolina and the Institutional Review Board at Oregon Health and Science University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsSODSphincter of Oddi disordersDGBIDisorders of gut-brain interactionCBDCommon bile ductiRAPIdiopathic recurrent acute pancreatitisMASLDMetabolic dysfunction associated steatotic liver diseaseRESPOnDResults of Ercp for SPhincter of Oddi DisordersPROMPatient-reported outcome measuresSVIStent vs. Indomethacin trialIBSIrritable bowel syndromeULNUpper limit of normalPGICPatient Global Impression of ChangeRAPIDRecurrent Abdominal Pain Intensity and DisabilityEPISODEvaluating Predictors & Interventions in Sphincter of Oddi Dysfunction